LCI Industries(LCII) - 2024 Q2 - Earnings Call Presentation
2024-08-06 20:56
LCI Industries Q2 2024 Earnings Conference Call August 6, 2024 INDUSTRIES Whenever, wherever, we make your experience better. Forward-Looking Statements This presentation contains certain "forward-looking statements" with respect to our financial condition, results of operations, profitability, margin growth, business strategies, operating efficiencies or synergies, competitive position, growth opportunities, acquisitions, plans and objectives of management, markets for the Company's common stock, the impac ...
Builders FirstSource(BLDR) - 2024 Q2 - Earnings Call Presentation
2024-08-06 20:44
Footnote Q2 2024 Earnings Presentation D A V E R U S H , C E O P E T E R J A C K S O N , C F O A U G U S T 6 , 2 0 2 4 Safe Harbor & Non-GAAP Financial Measures Cautionary Notice Statements in this presentation and the schedules hereto that are not purely historical facts or that necessarily depend upon future events, including statements about forecasted financial performance or other statements about anticipations, beliefs, expectations, hopes, synergies, intentions or strategies for the future, may be fo ...
Kenvue (KVUE) - 2024 Q2 - Earnings Call Presentation
2024-08-06 20:43
业绩总结 - 公司2024年第二季度有机增长率为+1.5%,较去年同期略有下降[11] - 调整后的毛利率较去年同期增加了410个基点,达到61.6%[12] - 2024年第二季度调整后的净收入为574百万美元,较去年同期略有下降[64] - 2024年第二季度调整后的每股收益为0.32美元[66] 品牌投资 - 公司品牌激活投资较去年同期增加了约20%[13] - 公司计划继续加大品牌投资,预计年度增长率为20%[62] 业务展望 - 公司预计2024年的净销售增长率为1.0%-3.0%[68] - 公司预计2024年调整后的毛利率将扩张约150个基点[17] - 公司预计2024财年的有效税率为26.5%至27.5%[100] 部门增长 - 2024年第二季度皮肤保健和美容部门的有机增长率为1.9%[86] - 2024年第二季度Essential Health部门的有机增长率为4.3%[86] - 2023年第二季度Essential Health部门的有机增长率为0.5%[82] - 2023年第二季度Essential Health部门的有机增长率为6.3%[82] 其他信息 - 调整后的有效税率为25.7%至30.8%[99] - 调整后的稀释每股收益为0.32至0.68美元[102] - 公司自由现金流为0.5亿美元[104]
AngloGold Ashanti plc(AU) - 2024 Q2 - Earnings Call Presentation
2024-08-06 20:34
业绩总结 - AngloGold Ashanti的调整后的EBITDA达到11.18亿美元,同比增长65%[15] - 公司2024年上半年黄金产量为1.254Moz,同比增长2%[82] - 调整后的净利润为3.13亿美元,同比增长413%[82] - 每股股利为22美分,同比增长450%[82] - 自由现金流为2.06亿美元,去年同期为-2.05亿美元[82] 业绩展望 - 集团2024年的黄金产量预期为2,650至2,850千盎司[101] - 集团总现金成本预期为1,075至1,175美元/盎司[101] 业务表现 - 澳大利亚和几内亚在2024年第二季度表现强劲,Siguiri产量同比增长67%,Tropicana产量同比增长38%[16] - 巴西地区实现强劲复苏,现金成本下降18%,自由现金流实现1.93亿美元的转正[12] - Obuasi矿山在2024年上半年产量稳定,预计下半年将有显著增长,2024年现金流预计健康[30] - Sunrise Dam矿山地下矿石开采量达到全潜力目标,2024年平均每月地下矿石开采量为240千吨[48] 财务状况 - 调整后的净债务与调整后的EBITDA比率为3.00倍[98] 策略和管理 - 公司通过运营改进在2022年至2024年上半年间实现了约4.64亿美元的增量EBITDA收益[56] - 公司有三个世界级项目在有机增长管道中,包括位于加纳的Obuasi项目、位于美国内华达州的项目和位于哥伦比亚的Quebradona项目[62] - 持续投资增长项目和维持资本支出,确保未来安全稳定运营[112]
Baxter(BAX) - 2024 Q2 - Earnings Call Presentation
2024-08-06 20:27
业绩总结 - 公司第二季度2024年销售额达到37.4亿美元,同比增长3%[14] - 调整后的毛利率为41.2%,同比增长80个基点[20] - 调整后的每股收益为0.68美元,同比增长24%[22] - 公司提高了全年销售额和调整后每股收益的财务展望[10] - 公司持续执行资本配置计划,包括债务偿还计划和股息支付[12] 未来展望 - 全年2024年,Baxter预计销售增长率约为3%[62] - 药品部门预计销售增长率约为7%[66] - 肾脏护理部门预计销售增长率为1%至2%[66] - 预计Baxter公司2024年第三季度持续运营销售增长率为3%-4%,在恒定货币下为4%-5%[122] - 预计Baxter公司2024年全年医疗产品和疗法销售增长率约为5%,在恒定货币下为约5%[123] 新产品和新技术研发 - Infusion Therapies and Technologies产品类别的净销售增长率为4%,在恒定货币汇率下增长率为5%[115] 市场扩张和并购 - 公司拥有21亿美元的现金及现金等价物,并可获得27亿美元的美元和欧元信贷额度[33] 负面信息 - 公司在2023年的自由现金流为-14亿美元[107]
GLOBALFOUNDRIES(GFS) - 2024 Q2 - Earnings Call Presentation
2024-08-06 20:25
1 Second Quarter 2024 Financial Results (unaudited) August 6, 2024 Disclaimer This presentation and the accompanying oral presentation include "forward-looking statements," that reflect our current expectations and views of future events. These forward-looking statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995 and include but are not limited to, statements regarding our financial outlook, future guidance, product development, business strategy ...
Bayer(BAYRY) - 2024 Q2 - Earnings Call Presentation
2024-08-06 19:02
///////////// Health for all, Hunger for none Q2 2024 Investor Call A u g u s t 0 6 , 2 0 2 4 Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Thes ...
Kemper(KMPR) - 2024 Q2 - Earnings Call Presentation
2024-08-06 11:24
Second Quarter 2024 Earnings August 5, 2024 Earnings Call Presentation – 2Q 2024 Preliminary Matters Cautionary Statements Regarding Forward-Looking Information This presentation may contain or incorporate by reference information that includes or is based on forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. We caution investors that these forward-looking statements are not guarantees of future performance, and actual results ...
Definitive Healthcare (DH) - 2024 Q2 - Earnings Call Presentation
2024-08-06 10:50
业绩总结 - 第二季度2024年营收增长5%[12] - 调整后的EBITDA利润率较去年同期扩大450个基点,达到33%[14] - 调整后的运营利润率较去年同期增长400个基点,达到30%[20] - 调整后的EBITDA较去年同期增长21%,达到20.9亿美元[21] - 订阅收入同比增长5%,专业服务收入同比增长3%[23] 用户数据 - 企业客户数量为537,同比增长32%[13] 未来展望 - 预计2024年第三季度营收为6.1 - 6.25亿美元,全年营收为24.7 - 25.1亿美元[38] - 预计2024年全年调整后的EBITDA利润率将扩大[42] 负面信息 - 2024年财务报告显示,其他非核心项目现金支出为2,438,000美元,增长超过100%[75] 其他新策略和有价值的信息 - 2024年6月30日,赞助商持有(按转换后计算)的股份为77,778,491股,管理层、董事和员工持有的股份为25,511,352股[56] - 2024年6月30日,已授予(按转换后计算)的股份为117,053,339股,控股股份占比为75.0%,非控股股份占比为25.0%[57] - 2024年6月30日,未投放的Class A RSUs为9.2M,未投放的Class B MIUs为0.4M[62]
EverQuote(EVER) - 2024 Q2 - Earnings Call Presentation
2024-08-06 09:05
Investor Presentation August 2024 Disclaimer This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this presentation, including statements regarding our future results of operations and financial position, business strategy and plans, and objectives of management for future operations, are forwar ...